| Ytd | 116.25% | |
| 1y | 118.07% |
| Open | 2.48 | Prev Close | 2.48 | Low | 2.48 | High | 2.55 | Mkt Cap | 55.74M |
| Vol | 39.16K | Avg Vol | 1.25M | EPS | -2.50 | P/E | -0.99 | Forward P/E | -0.70 |
| Beta | -0.07 | Short Ratio | 2.01 | Inst. Own | 75.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.86 | 200-d Avg | 1.40 | 1yr Est | 14.50 |
BOLD News
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 2
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASD
NEW YORK, June 23, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Asso
Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi
US stocks lower, Nasdaq falls 500 points. Dow down 0.04%, Nasdaq 1.91%, S&P 500 1.27%. Consumer
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge
US stocks down as Dow falls 300 points, while S&P 500 and NASDAQ also decrease. Consumer staples
Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market sessi
Boundless Bio, Inc. (Nasdaq: BOLD) and Serapha Bio, Inc., a privately held biotechnology company dev
Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo
Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provi
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin deg
TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OT
Boundless Bio offers a highly asymmetric risk/reward profile, trading at a $25M valuation with $107.
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncolog
Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status,
Dot's brings its iconic buttery-rich pretzels and bold Original seasoning to Snack Mix! HERSHEY, Pa.
KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncolog
Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism a
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 20
It's Not About the Water, It's About the Drip. bubba®'s New Look, Fashion-forward Finishes, And Bold
Approved by Archax 12/01/2026 Don't invest unless you're prepared to lose all the money you invest.